AbbVie (ABBV) Operating Income Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Op. Inc Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
81.11% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
3.64% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
12.96% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-203.67% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
11.54% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
14.90% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
2.04% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
-42.48% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
12.96% |
| Dec 31, 2025 |
-6.18% |
| Sep 30, 2025 |
-25.49% |
| Jun 30, 2025 |
14.10% |
| Mar 31, 2025 |
-7.50% |
| Dec 31, 2024 |
-31.88% |
| Sep 30, 2024 |
-3.82% |
| Jun 30, 2024 |
-3.44% |
| Mar 31, 2024 |
-11.98% |
| Dec 31, 2023 |
-5.22% |
| Sep 30, 2023 |
-11.18% |
| Jun 30, 2023 |
81.73% |
| Mar 31, 2023 |
-8.41% |
| Dec 31, 2022 |
11.62% |
| Sep 30, 2022 |
20.71% |
| Jun 30, 2022 |
-1.04% |
| Mar 31, 2022 |
16.15% |
| Dec 31, 2021 |
59.77% |
| Sep 30, 2021 |
10.88% |
| Jun 30, 2021 |
17.15% |
| Mar 31, 2021 |
12.22% |
| Dec 31, 2020 |
28.18% |
| Sep 30, 2020 |
6.51% |
| Jun 30, 2020 |
-34.38% |
| Mar 31, 2020 |
14.39% |
| Dec 31, 2019 |
19.57% |
| Sep 30, 2019 |
3.49% |
| Jun 30, 2019 |
241.36% |
| Mar 31, 2019 |
9.73% |
| Dec 31, 2018 |
-46.67% |
| Sep 30, 2018 |
18.78% |
| Jun 30, 2018 |
101.62% |
| Mar 31, 2018 |
19.83% |
| Dec 31, 2017 |
84.63% |
| Sep 30, 2017 |
41.05% |
| Jun 30, 2017 |
20.67% |
| Mar 31, 2017 |
21.23% |
| Dec 31, 2016 |
14.66% |
| Sep 30, 2016 |
19.86% |
| Jun 30, 2016 |
-27.28% |
| Mar 31, 2016 |
20.41% |
| Dec 31, 2015 |
5.08% |
| Sep 30, 2015 |
5.70% |
| Jun 30, 2015 |
-38.12% |
| Mar 31, 2015 |
19.93% |